N-Myc promotes therapeutic resistance development of neuroendocrine prostate cancer by differentially regulating miR-421/ATM pathway
Sign Up to like & getrecommendations! Published in 2019 at "Molecular Cancer"
DOI: 10.1186/s12943-019-0941-2
Abstract: BackgroundMYCN amplification or N-Myc overexpression is found in approximately 40% NEPC and up to 20% CRPC patients. N-Myc has been demonstrated to drive disease progression and hormonal therapeutic resistance of NEPC/CRPC. Here, we aim to… read more here.
Keywords: therapeutic resistance; resistance; atm pathway; 421 atm ... See more keywords